The Latest Breaking News from Pfizer

Pfizer Inc's (NYSE:PFE) deal with Washington isn't just a handshake in the Oval Office — it's a seismic jolt to America's drug-pricing game. By agreeing to sell medicines on the government's new TrumpRx platform at steep discounts and extend "most favored nation" (MFN) pricing to Medicaid, Pfizer bought itself a…

Mark Cuban, the billionaire entrepreneur and investor, has given a cautious “B” grade to President Donald Trump’s new online drug store venture, TrumpRx.gov. 

TrumpRx will slash US drug prices by up to 85% under a new deal with Pfizer, bringing costs in line with other nations and boosting US investment.

Weird how one happens before the other.

Senate Democrats voted down a Republican bill to keep funding the government, putting it on a near certain path to a shutdown. Key US politics stories from 30 September 2025

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.28%. December E-mini S&P futures (ESZ25 ) rose +0.39%, and December E-mini Nasdaq futures...

The Trump administration on Tuesday announced a deal granting Pfizer a three-year reprieve on planned tariffs as the pharmaceutical giant vowed to voluntarily lower the prices of unspecified drugs for US purchase.

On Tuesday, Pfizer Inc. (NYSE:PFE) announced a historic agreement with the Trump Administration to ensure U.S. patients pay lower prices for their prescription medicines.

Donald Trump has struck a headline-grabbing deal with Pfizer to slash US drug prices, launching a TrumpRx platform that bypasses intermediaries and raises major questions over enforcement and patient impact.